These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11825329)

  • 1. New concepts in the drug therapy of Alzheimer's disease.
    Hake AM; Farlow MR
    Expert Opin Pharmacother; 2001 Dec; 2(12):1975-83. PubMed ID: 11825329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy against amyloid pathology in Alzheimer's disease.
    Galimberti D; Ghezzi L; Scarpini E
    J Neurol Sci; 2013 Oct; 333(1-2):50-4. PubMed ID: 23299047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches.
    Hake AM
    Semin Neurol; 2002 Mar; 22(1):71-4. PubMed ID: 12170395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
    Omerovic M; Hampel H; Teipel SJ; Buerger K
    World J Biol Psychiatry; 2008; 9(1):69-75. PubMed ID: 17886162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current pharmacotherapy for Alzheimer's disease.
    Lleó A; Greenberg SM; Growdon JH
    Annu Rev Med; 2006; 57():513-33. PubMed ID: 16409164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity.
    Mullane K; Williams M
    Curr Protoc Pharmacol; 2019 Mar; 84(1):e57. PubMed ID: 30802363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():359-375. PubMed ID: 30273553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological treatment of Alzheimer's Disease.
    Bianchetti A; Ranieri P; Margiotta A; Trabucchi M
    Aging Clin Exp Res; 2006 Apr; 18(2):158-62. PubMed ID: 16702787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
    Popp J; Arlt S
    Curr Opin Psychiatry; 2011 Nov; 24(6):556-61. PubMed ID: 21934621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
    Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
    Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
    Macdonald IR; Rockwood K; Martin E; Darvesh S
    J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents.
    Lahiri DK; Rogers JT; Greig NH; Sambamurti K
    Curr Pharm Des; 2004; 10(25):3111-9. PubMed ID: 15544501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease.
    Haas C
    J Alzheimers Dis; 2012; 28(2):241-81. PubMed ID: 21987594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug therapy strategies in Alzheimer's disease].
    Lacomblez L
    Rev Prat; 1998 Nov; 48(17):1913-7. PubMed ID: 9854394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reappraising neurotransmitter-based strategies.
    Möller HJ
    Eur Neuropsychopharmacol; 1999 Apr; 9 Suppl 2():S53-9. PubMed ID: 10332935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease.
    Verhoeff NP
    Expert Rev Neurother; 2005 Mar; 5(2):277-84. PubMed ID: 15853497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.